What question did this study set out to answer?

The research aims to explore how VGLL4 influences the Wnt/β-catenin signaling pathway in acute myeloid leukemia (AML).

April 17, 2026Open Access

VGLL4 regulates the Wnt/β-catenin signaling pathway and acts as an oncogenic factor in acute myeloid leukemia

Key Points

The research aims to explore how VGLL4 influences the Wnt/β-catenin signaling pathway in acute myeloid leukemia (AML).
Investigated VGLL4's oncogenic role in AML
Analyzed its effects on the Wnt/β-catenin pathway
Proposed VGLL4 as a therapeutic target
VGLL4 activates the Wnt/β-catenin signaling pathway
VGLL4 is identified as an oncogenic factor in AML
Potential for VGLL4-targeted therapies in treating AML

Abstract

VGLL4 acts as an oncogenic factor in AML, potentially through activating the Wnt/β-catenin pathway. Thus, we propose VGLL4 as a promising molecular target for AML therapy.

Read Full Paperexternally

Demander à l'IA

Bookmark

View Full Paper